Pharmaceutical development of a parental lyophilised formulation of the investigational anticancer agent ES-285.HCl

PDA Journal of Pharmaceutical Science and Technology

Volumn 59, Issue 4, 2005, Pages 246-257

  Den Brok, Monique W J ^a   Nuijen, Bastiaan ^a   Meijer, Dieuwke M ^a   Millán, Elena ^b   Manada, Consuelo ^b   Beijnen, Jos H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b PHARMAMAR S A   (Spain)

Author keywords

2 hydroxypropyl cyclodextrine; Characterization; ES 285.HCl; Formulation; Lyophilization

Indexed keywords

2 AMINOOCTADECAN 3 OL; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTINEOPLASTIC AGENT; ES 285; UNCLASSIFIED DRUG; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ALKANE; BETA CYCLODEXTRIN DERIVATIVE; ES-285; EXCIPIENT; LIPID; NEW DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DESIGN; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; HUMAN; LONG TERM CARE; MATHEMATICAL ANALYSIS; PHASE 1 CLINICAL TRIAL; REACTION OPTIMIZATION; CHEMISTRY; DRUG CONTAMINATION; DRUG STORAGE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SOLUBILITY; STANDARD;

ALKANES; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; DRUG COMPOUNDING; DRUG CONTAMINATION; DRUG STABILITY; DRUG STORAGE; DRUGS, INVESTIGATIONAL; EXCIPIENTS; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; SOLUBILITY;

EID: 25144491627     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cuadros, R.; Montejo, D.G.; Wandosell, F.; Faircloth, G.; Fernandez-Sousa, J.M.; Avila, J. The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett. 2000, 152, 23-29.
2. Chrzanowska-Wodnicka, M.; Burridge, K. Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J. Cell Biol. 1996, 133, 1403-1415.
3. th ed.; Council of Europe, Strasbourg, 2002.
4. th ed.; United States Pharmacopoeial Convention Inc., Rockville, MD, 2000.
5. Den Brok, M. W. J.; Nuijen, B.; Miranda, E.; Floriano, P.; Munt, S.; Manzanares, I.; Beijnen, J. H. Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285.HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form. J. Chrom. A. 2003, 1020, 251-258.
6. Higuchi, T.; Connors, K. A. Phase-solubility techniques. Adv. Anal. Chem. Instr. 1965, 7, 117-212.
7. Rao, V. M.; Stella, V. J. When can cyclodextrins be considered for solubilization purposes?. J. Pharm. Sci. 2003, 92(927), 927-932.
8. European Commission. Medicinal products for human and veterinary use- Good manufacturing practices. 1997, Vol. 4. Available at: http:// pharmacos.eudra.org/F2/eudralex/vol-4/home.htm
9. Frijlink, H. W.; Visser, J.; Drenth, B. F. Determination of cyclodextrins in biological fluids by high-performance liquid chromatography with negative colorimetric detection using post-column complexation with phenolphthalein. J. Chromatogr. 1987, 415, 325-333.
10. ICH Steering Committee, ICH Q1A R Stability testing guidelines: stability testing of new drug substances and products, European Agency for the Evaluation of Medicinal Products, International Commission on Harmonisation; London (CPMP/ICH/2736/99), 2000.
11. Bekers, O.; Uijtendaal, E. V.; H. Beijnen, J. H.; Bult, A.; Underberg, W. J. M. Cyclodextrins in the pharmaceutical field. Drug. Dev. Ind. Pharm. 1991, 17, 1503-1549.
12. Uekama, K.; Hirayama, F.; Irie, T. Cyclodextrin drug carrier system. Chem. Rev. 1998, 98, 2045-2076.
13. Brewster, M. E.; Simpkins, J. W.; Hora, M. S.; Stern, W. C.; Bodor, N. The potential use of cyclodextrins in parenteral formulations. J. Parenter. Sci. Technol. 1989, 43, 231-240.
14. Loftsson, T.; Brewster, M. E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85, 1017-1025.
15. Carpenter, T. O.; Gerloczy, A.; Pitha, J. Safety of parenteral hydroxypropyl beta-cyclodextrin. J. Pharm. Sci. 1995, 84, 222-225.
16. Irie, T.; Uekama, K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 1997, 86, 147-162.
17. Szente, L.; Szejtli, J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 1999, 36, 17-28.
18. Boogaerts, M. A.; Maertens, J.; Van Der, G. R; Bosly, A.; Michaux, J. M.; Van Hoof, A.;. Cleeren, M.; Wostenborghs, R.; De Beule, K. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob. Agents Chemother. 2001, 45, 981-985.
19. Stevens, D. A. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999, 19, 603-611.
20. Slain, D.; Rogers, P. D.; Cleary, J. D.; Chapman, S. W. Intravenous intraconazol. Ann Pharmacother. 2001, 35, 720-725.
21. Loftsson, T.; Frioriksdóttir, H. The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin. Int. J. Pharm. 1998, 163, 115-121.
22. Ribeiro, L. S.; Ferreira, D. C.; Veiga, F. J. Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with beta-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur. J. Pharm. Sci. 2003, 20, 253-266.
23. Mura, P.; Faucci, M. T.; Bettinetti, G. P. The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-beta- cyclodextrin. Eur. J. Pharm. Sci. 2001, 13, 187-194.
24. Jarho, P.; Pate, D. W.; Brenneisen, R.; Jarvinen, T. Hydroxypropyl-beta- cyclodextrin and its combination with hydroxypropyl-methylcellulose increases aqueous solubility of delta9-tetrahydrocannabinol. Life Sci. 1998, 63, L381-L384.
25. Ganzerli, G.; van Santvliet, L.; Verschuren, E.; Ludwig, A. Influence of beta-cyclodextrin and various polysaccharides on the solubility of fluorescein and on the rheological and mucoadhesive properties of ophthalmic solutions. Pharmazie 1996, 51, 357-362.
26. Royall, P. G.; Craig, D. Q.; Doherty, C. Characterisation of the glass transition of an amorphous drug using modulated DSC. Pharm. Res. 1998, 15, 1117-1121.
27. Skrabanja, A. T.; de Meere, A. L.; de Ruiter, R. A.; van den Oetelaar, P. J. Lyophilization of biotechnology products. PDA. J. Pharm. Sci. Technol. 1994, 48, 311-317.
28. Jennings, T. A. "Supercooling," http://www. phase-technologies.com/html/vol._5_no._5.html, 2002.
29. Zimmerman, J. A.; Ballard, J. M.; Wang, H.; Wu, A.; Gallagher, K. A. Extraction of o-phenylphenol from silicone tubing by a sulfobutylether cyclodextrin formulation. Int. J. Pharm. 2003, 267, 113-120.
30. Stafford, J. Calculating the risk of batch failure in the manufacture of drug products. Drug Dev. Ind. Pharm. 1999, 25, 1083-1091.